Search

Displaying results 3921 - 3930 of 9322 in total
  1. Drug

    Alimemazine

    go.drugbank.com/drugs/DB01246
    ApprovedVet approvedWithdrawn

    A phenothiazine derivative that is used as an antipruritic.

  2. Drug

    Alphaprodine

    go.drugbank.com/drugs/DB13160
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Aceprometazine

    go.drugbank.com/drugs/DB01615
    Experimental

    Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.

  4. Drug

    Proparacaine

    go.drugbank.com/drugs/DB00807
    ApprovedVet approved

    Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

  5. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  6. Drug

    Bethanidine

    go.drugbank.com/drugs/DB00217
    Approved

    A guanidinium antihypertensive agent that acts by blocking adrenergic transmission.

  7. Drug

    gamma-Aminobutyric acid

    go.drugbank.com/drugs/DB02530
    ApprovedInvestigational

    The most common inhibitory neurotransmitter in the central nervous system.

  8. Drug

    ATN-161

    go.drugbank.com/drugs/DB05491
    Investigational

    expected to extend to a variety of cancers. … This approach targeting both the tumor vasculature and the cancer cells themselves, may be effective in single therapy as well as combination therapy.

  9. Drug

    CYT006-AngQb

    go.drugbank.com/drugs/DB05739
    Investigational

    It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure

  10. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    It is currently marketed in Canada by Valeant under the tradename Cophylac.